Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

NCT03049189 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: 177Lu-edotreotide PRRT
DRUG: Everolimus
OTHER: Amino-Acid Solution

Sponsor

ITM Solucin GmbH

Collaborators

[object Object]
[object Object]